SCHEMBL8937244

SCHEMBL8937244

COc1ccc(/C(=C\C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2ccc(OC)c(OC)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.72
L3MBTL1 Q9Y468 1/20 0.72
TP53 P04637 2/20 0.56
KDM4E B2RXH2 1/20 0.56
CYP1A2 P05177 1/20 0.56
POLB P06746 2/20 0.54
DRD3 P35462 1/20 0.52
GAA P10253 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
CYP2C19 P33261 1/20 0.50
GPR183 P32249 1/20 0.50
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937251 1.00 ALDH1A1 (0.72) ALDH1A1L3MBTL1TP53KDM4ECYP1A2
SCHEMBL8937249 1.00 ALDH1A1 (0.72) ALDH1A1L3MBTL1TP53KDM4ECYP1A2
SCHEMBL8937620 0.95 ALDH1A1 (0.79) ALDH1A1L3MBTL1TP53KDM4ECYP1A2
SCHEMBL8937573 0.94 ALDH1A1 (0.64) ALDH1A1L3MBTL1KDM4ECYP1A2POLB
SCHEMBL8937334 0.91 ALDH1A1 (0.58) ALDH1A1L3MBTL1TP53KDM4ECYP1A2
SCHEMBL8937708 0.91 ALDH1A1 (0.70) ALDH1A1L3MBTL1KDM4ECYP1A2POLB
SCHEMBL8937342 0.91 ALDH1A1 (0.58) ALDH1A1L3MBTL1TP53KDM4ECYP1A2
SCHEMBL8937707 0.91 ALDH1A1 (0.70) ALDH1A1L3MBTL1KDM4ECYP1A2POLB
SCHEMBL8937338 0.91 ALDH1A1 (0.58) ALDH1A1L3MBTL1TP53KDM4ECYP1A2
SCHEMBL8937543 0.90 LMNA (0.57) ALDH1A1L3MBTL1KDM4ECYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed